Persistent corneal epithelial defects Pipeline Analysis, 2025 | PCEDs Clinical Trials | Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma

Posted on
by

Persistent corneal epithelial defects Pipeline Analysis, 2025 | PCEDs Clinical Trials | Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma
Persistent corneal epithelial defects Pipeline Analysis
DelveInsight’s, “Persistent Corneal Epithelial Defects (PCEDs) – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Persistent Corneal Epithelial Defects (PCEDs) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight’s Persistent corneal epithelial defects Clinical Trials Analysis Report provides deep insights to support strategic decision-making for Persistent corneal epithelial defects pipeline expansion, competitive positioning, and partnership identification in the rare neurodegenerative disease space.

Persistent corneal epithelial defects (PCEDs) Overview:

The cornea, the transparent outer layer of the eye, is essential for vision as it bends most incoming light evenly toward the lens. Its layered epithelial surface not only protects against infections through tightly linked cells but also preserves a smooth optical surface by continually regenerating basal cells. Persistent Corneal Epithelial Defects (PCEDs)—also referred to as PEDs—arise when the corneal surface fails to heal within 10–14 days after injury, even with appropriate supportive care. Such defects can compromise both the epithelial and stromal layers, leaving the eye susceptible to infections, stromal ulcers, perforation, scarring, and serious vision loss.

Download our report @ https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Persistent corneal epithelial defects (PCEDs) Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Persistent corneal epithelial defects (PCEDs) Therapeutics Market.

Key Takeaways from the Persistent corneal epithelial defects (PCEDs) Pipeline Report

  • DelveInsight’s Persistent Corneal Epithelial Defects (PCEDs) Pipeline Report highlights a dynamic landscape, with over 5 companies actively developing 5+ therapeutic candidates for PCEDs.

  • In April 2023, the FDA granted Fast Track designation to KPI-012, a human mesenchymal stem cell secretome (MSC-S) therapy developed by Kala Pharmaceuticals. This designation is intended to accelerate the development and review of therapies addressing serious conditions with unmet medical needs. KPI-012 is currently being assessed in the Phase 2b CHASE trial, targeting PCEDs arising from multiple causes, including neurotrophic keratitis and chemical injuries. Early study findings demonstrated encouraging safety outcomes, and Kala expects to release top-line safety and efficacy data in Q1 2024.

  • Leading companies in the PCEDs space include Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma, among others, all working to advance innovative therapies. Prominent emerging candidates include KPI-012, Nexagon, and more, reflecting significant progress in improving the PCEDs treatment landscape.

Persistent corneal epithelial defects (PCEDs) Pipeline Analysis

The Persistent corneal epithelial defects (PCEDs) pipeline insights report 2025, provides insights into:

  • Provides comprehensive insights into key companies developing therapies in the Persistent corneal epithelial defects (PCEDs) Market.

  • Categorizes Persistent corneal epithelial defects (PCEDs) therapeutic companies by development stage: early, mid, and late-stage.

  • Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

  • Reviews emerging Persistent corneal epithelial defects (PCEDs) drugs under development based on:

    • Stage of development

    • Persistent corneal epithelial defects (PCEDs) Route of administration

    • Target receptor

    • Monotherapy vs. combination therapy

    • Persistent corneal epithelial defects (PCEDs) Mechanism of action

    • Molecular type

  • Offers detailed analysis of:

    • Company-to-company and company-academia collaborations

    • Persistent corneal epithelial defects (PCEDs) Licensing agreements

    • Funding and investment activities supporting future Persistent corneal epithelial defects (PCEDs) market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Persistent corneal epithelial defects (PCEDs) Emerging Drugs

  • KPI-012: Kala Pharmaceuticals

Kala Pharmaceuticals is developing KPI-012 for the treatment of persistent corneal epithelial defect (PCED), a rare disorder that impairs corneal healing. The company is also investigating its potential in other rare front-of-eye diseases, including partial limbal stem cell deficiency and moderate-to-severe Sjögren’s syndrome. Currently in a Phase II clinical trial slated for completion in February 2024, KPI-012 is derived from a proprietary mesenchymal stem cell secretome (MSC-S) platform. Kala advanced this program following its acquisition of Combangio, Inc. in November 2021.

  • Nexagon: Eyevance/Amber Ophthalmics

NEXAGON is a first-in-class, unmodified antisense oligodeoxynucleotide that targets connexin43 (Cx43), a membrane protein upregulated following injury or in chronic disease. Excess Cx43 triggers abnormal hemichannel opening, leading to ATP release and activation of inflammatory pathways that drive vessel leakage and limbal ischemia. By blocking Cx43, NEXAGON helps reduce inflammation, repair limbal microvasculature, and promote regeneration of the corneal epithelium.

Major trends shaping the clinical trial and competitive landscape for Persistent corneal epithelial defects:

  • Shift Toward Regenerative Therapies: Increasing focus on stem cell-based therapies, growth factors, and biologics to promote corneal healing.

  • Emergence of Novel Drug Modalities: Development of antisense oligonucleotides, gene therapies, and nanosuspensions targeting underlying disease mechanisms.

  • Expansion of Clinical Trials: Growth in early- and mid-stage trials exploring multiple therapeutic approaches, including combination therapies.

  • Strategic Collaborations: Partnerships between biotech, pharma, and academic institutions to accelerate R&D and share technological expertise.

  • Regulatory Support: Orphan Drug, Fast Track, and RMAT designations facilitate expedited development for rare ocular disorders.

  • Patient-Centric Approaches: Incorporation of patient-reported outcomes, corneal healing metrics, and visual function assessments in clinical studies.

  • Innovation in Formulations and Delivery: Focus on ocular nanosuspensions, topical applications, and controlled-release systems to improve efficacy and compliance.

  • Competitive Differentiation: Companies differentiating pipelines by mechanism of action, stage of development, and molecular type.

  • Real-World Evidence Integration: Leveraging real-world data and observational studies to support clinical development and market adoption.

Persistent corneal epithelial defects (PCEDs) Companies

More than five key companies are actively working on therapies for Persistent Corneal Epithelial Defects (PCEDs), with several candidates already advancing into Phase II clinical trials.

DelveInsight’s report covers around 5+ products under different phases of Persistent corneal epithelial defects (PCEDs) clinical trials like

  • Persistent corneal epithelial defects (PCEDs) Late stage Therapies (Phase III)

  • Persistent corneal epithelial defects (PCEDs) Mid-stage Therapies (Phase II)

  • Persistent corneal epithelial defects (PCEDs) Early-stage Therapies (Phase I)

  • Persistent corneal epithelial defects (PCEDs) Pre-clinical and Persistent corneal epithelial defects (PCEDs) Discovery stage Therapies

  • Persistent corneal epithelial defects (PCEDs) Discontinued & Inactive Therapies

Persistent corneal epithelial defects (PCEDs) pipeline report provides the Persistent corneal epithelial defects (PCEDs) therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Persistent corneal epithelial defects (PCEDs) Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Persistent corneal epithelial defects (PCEDs) Therapies and Key Persistent corneal epithelial defects (PCEDs) Companies: Persistent corneal epithelial defects (PCEDs) Clinical Trials and recent advancements

Persistent corneal epithelial defects (PCEDs) Pipeline Therapeutic Assessment

• Persistent corneal epithelial defects (PCEDs) Assessment by Product Type

• Persistent corneal epithelial defects (PCEDs) By Stage

• Persistent corneal epithelial defects (PCEDs) Assessment by Route of Administration

• Persistent corneal epithelial defects (PCEDs) Assessment by Molecule Type

Persistent corneal epithelial Report Section Includes:

  • Persistent corneal epithelial competitive landscape clinical trials

  • Persistent corneal epithelial emerging drugs analysis

  • Persistent corneal epithelial investigational drugs report

  • Persistent corneal epithelial clinical trial trends analysis

  • Persistent corneal epithelial pipeline benchmarking report

  • Persistent corneal epithelial drug pipeline competitive intelligence

  • Persistent corneal epithelial competitive landscape

Download Persistent corneal epithelial defects (PCEDs) Sample report to know in detail about the Persistent corneal epithelial defects (PCEDs) treatment market @ Persistent corneal epithelial defects (PCEDs) Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Persistent corneal epithelial defects (PCEDs) Current Treatment Patterns

4. Persistent corneal epithelial defects (PCEDs) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Persistent corneal epithelial defects (PCEDs) Late-Stage Products (Phase-III)

7. Persistent corneal epithelial defects (PCEDs) Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Persistent corneal epithelial defects (PCEDs) Discontinued Products

13. Persistent corneal epithelial defects (PCEDs) Product Profiles

14. Persistent corneal epithelial defects (PCEDs) Key Companies

15. Persistent corneal epithelial defects (PCEDs) Key Products

16. Dormant and Discontinued Products

17. Persistent corneal epithelial defects (PCEDs) Unmet Needs

18. Persistent corneal epithelial defects (PCEDs) Future Perspectives

19. Persistent corneal epithelial defects (PCEDs) Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Persistent corneal epithelial defects (PCEDs) Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/